Metacrine to Present at 2021 Jefferies Healthcare Conference

Rhea-AI Summary

Metacrine, Inc. (NASDAQ:MTCR) announced that CEO Preston Klassen will present virtually at the 2021 Jefferies Healthcare Conference on June 4, 2021, at 11:00 a.m. ET. A live webcast of the presentation will be available, with a replay accessible for 30 days post-conference.

Metacrine focuses on developing therapies for liver and gastrointestinal diseases, leveraging its proprietary FXR platform. The company is currently testing two product candidates, MET409 and MET642, for NASH treatment in clinical trials.

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Jefferies Healthcare Conference at 11:00 a.m. ET on Friday, June 4, 2021.

A live webcast of the presentation will be available at https://investors.metacrine.com/events-and-presentations.   A replay of the webcast will be archived for 30 days following the conference.  

About Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH. To learn more, visit www.metacrine.com.

FAQ

What is the date of Metacrine's presentation at the Jefferies Healthcare Conference?

Metacrine's presentation is scheduled for June 4, 2021, at 11:00 a.m. ET.

Where can I watch the Metacrine presentation live?

The live webcast of Metacrine's presentation will be available on their investors' page.

What are MET409 and MET642 being tested for?

MET409 and MET642 are being investigated as potential treatments for NASH.

What is the focus of Metacrine, Inc.?

Metacrine focuses on developing differentiated therapies for liver and gastrointestinal diseases.

What is the stock symbol for Metacrine?

The stock symbol for Metacrine is MTCR.